Cargando…

Sustained cancer clinical trial activity in a French hospital during the first wave of the COVID-19 pandemic

Detalles Bibliográficos
Autores principales:	Bayle, Arnaud, Baldini, Capucine, Martin-Romano, Patricia, Michot, Jean-Marie, Champiat, Stéphane, Bahleda, Rastilav, Gazzah, Anas, Marabelle, Aurélien, Verlingue, Loic, Geraud, Arthur, Morel, Daphné, Michiels, Stefan, Hollebecque, Antoine, Albiges, Laurence, Besse, Benjamin, Soria, Jean-Charles, Massard, Christophe, Barlesi, Fabrice, Postel-Vinay, Sophie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier Inc. 2021
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8243022/ https://www.ncbi.nlm.nih.gov/pubmed/34197735 http://dx.doi.org/10.1016/j.ccell.2021.06.010

Ejemplares similares

1617P Sustained cancer clinical trial activity during the COVID-19 pandemic
por: Bayle, A., et al.
Publicado: (2021)

Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers
por: Cabel, Luc, et al.
Publicado: (2018)

Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types
por: Martin‐Romano, Patricia, et al.
Publicado: (2020)

Predicting Immunotherapy Outcomes in Older Patients with Solid Tumors Using the LIPI Score
por: Pierro, Monica, et al.
Publicado: (2022)

Case Report: Response to Immunotherapy, Can Radiotherapy Be a Troublemaker?
por: Martin-Romano, Patricia, et al.
Publicado: (2021)

Time to progression ratio in cancer patients enrolled in early phase clinical trials: time for new guidelines?
por: Watson, Sarah, et al.
Publicado: (2018)

Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers
por: Baldini, Capucine, et al.
Publicado: (2022)

Phase I study of afatinib combined with nintedanib in patients with advanced solid tumours
por: Bahleda, Rastislav, et al.
Publicado: (2015)

Durvalumab for the management of urothelial carcinoma: a short review on the emerging data and therapeutic potential
por: Baldini, Capucine, et al.
Publicado: (2019)

Coronavirus disease (COVID-19) outbreak and phase 1 trials: should we consider a specific patient management?
por: Postel-Vinay, Sophie, et al.
Publicado: (2020)

A Case-Control Study Brings to Light the Causes of Screen Failures in Phase 1 Cancer Clinical Trials
por: Kempf, Emmanuelle, et al.
Publicado: (2016)

Kidney Diseases Associated With Anti-Vascular Endothelial Growth Factor (VEGF): An 8-year Observational Study at a Single Center
por: Izzedine, Hassan, et al.
Publicado: (2014)

Molecular guided therapy for advanced pancreatic cancer patients with PI3K activated mutation: vision or illusion?
por: Gazzah, Anas, et al.
Publicado: (2013)

Patient-reported tolerability of adverse events in phase 1 trials
por: Henon, Clémence, et al.
Publicado: (2017)

Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report
por: Michot, J.-M., et al.
Publicado: (2020)

How Much Can We Bet on Activity of BET Inhibitors Beyond NUT–Midline Carcinoma?
por: Martin-Romano, Patricia, et al.
Publicado: (2019)

1688P Outcome of older cancer patients infected with COVID-19 at Gustave Roussy Cancer Center
por: Hauchecorne, M., et al.
Publicado: (2020)

Genomic Instability and Protumoral Inflammation Are Associated with Primary Resistance to Anti–PD-1 + Antiangiogenesis in Malignant Pleural Mesothelioma
por: Danlos, François-Xavier, et al.
Publicado: (2023)

1639P Impact of COVID-19 on ongoing oncological and hematological treatment strategy
por: Bayle, A., et al.
Publicado: (2021)

Intratumoural administration and tumour tissue targeting of cancer immunotherapies
por: Melero, Ignacio, et al.
Publicado: (2021)

Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy
por: Recondo, Gonzalo, et al.
Publicado: (2020)

A microsimulation model to assess the economic impact of immunotherapy in non-small cell lung cancer
por: Legoupil, Clémence, et al.
Publicado: (2020)

Renal toxicities associated with pembrolizumab
por: Izzedine, Hassan, et al.
Publicado: (2018)

Impact of COVID-19 Pandemic on Cancer Research
por: Zon, Leonard, et al.
Publicado: (2020)

Severe COVID-19 in patients with hematological cancers presenting with viremia
por: Michot, J.M., et al.
Publicado: (2021)

Neurological complications induced by immune checkpoint inhibitors: a comprehensive descriptive case-series unravelling high risk of long-term sequelae
por: Plaçais, Léo, et al.
Publicado: (2021)

Oncogenic Fusions May Be Frequently Present at Resistance of EGFR Tyrosine Kinase Inhibitors in Patients With NSCLC: A Brief Report
por: Enrico, Diego, et al.
Publicado: (2020)

Next-Generation Sequencing on Circulating Tumor DNA in Advanced Solid Cancer: Swiss Army Knife for the Molecular Tumor Board? A Review of the Literature Focused on FDA Approved Test
por: Vasseur, Damien, et al.
Publicado: (2022)

Bamlanivimab + etesevimab therapy induces SARS-CoV-2 immune escape mutations and secondary clinical deterioration in COVID-19 patients with B-cell malignancies
por: Pommeret, F., et al.
Publicado: (2021)

Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors
por: Négrier, Sylvie, et al.
Publicado: (2017)

Synergizing liver systemic treatments with interventional oncology: friend or foe?
por: Jost, Raphaël, et al.
Publicado: (2022)

Chronic Plasma Exposure to Kinase Inhibitors in Patients with Oncogene-Addicted Non-Small Cell Lung Cancer
por: Geraud, Arthur, et al.
Publicado: (2020)

TP53 Mutation as a Prognostic and Predictive Marker in Sarcoma: Pooled Analysis of MOSCATO and ProfiLER Precision Medicine Trials
por: Nassif, Elise F., et al.
Publicado: (2021)

Beyond DNA repair: the novel immunological potential of PARP inhibitors
por: Chabanon, Roman M., et al.
Publicado: (2019)

Dose escalation phase 1 study of radiotherapy in combination with anti-cytotoxic-T-lymphocyte-associated antigen 4 monoclonal antibody ipilimumab in patients with metastatic melanoma
por: Boutros, Celine, et al.
Publicado: (2020)

Clinical significance of the loss of CD20 antigen on tumor cells in patients with relapsed or refractory follicular lymphoma
por: Michot, Jean-Marie, et al.
Publicado: (2021)

Unlikely association of nephrectomy post-mRCC with anti-VEGF-induced renal TMA
por: Izzedine, Hassane, et al.
Publicado: (2011)

Exomics and immunogenics: Bridging mutational load and immune checkpoints efficacy
por: Champiat, Stéphane, et al.
Publicado: (2014)

ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer
por: Fizazi, Karim, et al.
Publicado: (2015)

Impact of COVID-19 on healthcare organisation and cancer outcomes
por: Bardet, Aurelie, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8cb03b4eqird7g5ebo3jvsp039